Meeting
2018 ASCO Annual Meeting
Phase I study of afatinib and radiotherapy (RT) with or without temozolomide (TMZ) in newly diagnosed glioblastoma (GB).
Authors
Frank Saran
The Royal Marsden NHS Foundation Trust, London, United Kingdom
Frank Saran , Liam Welsh , Allan James , Catherine McBain , Rao Gattamaneni , Sarah Jefferies , Fiona Harris , Agnieszka Cseh , Karine Pemberton , Jennifer Schaible , Shaun Bender , Michael Brada
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT00977431
Citation
J Clin Oncol 36, 2018 (suppl; abstr 2036)
DOI
10.1200/JCO.2018.36.15_suppl.2036
Abstract #
2036
Poster Bd #
194
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Phase I and pharmacodynamic study of arsenic trioxide plus radiotherapy for newly diagnosed glioblastoma.
First Author: Samuel Ryu
Poster
2021 ASCO Annual Meeting
Phase 1 trial of drug resistant immunotherapy: A first-in-class combination of MGMT-modified γδ t cells and temozolomide chemotherapy in newly diagnosed glioblastoma.
First Author: Louis B. Nabors
Poster
2019 ASCO Annual Meeting
Full enrollment results from an extended phase I, multicenter, open label study of marizomib (MRZ) with temozolomide (TMZ) and radiotherapy (RT) in newly diagnosed glioblastoma (GBM).
First Author: Warren P. Mason
Poster
2019 ASCO Annual Meeting
A TITE-CRM phase I/II study of disulfiram and copper with concurrent radiation therapy and temozolomide for newly diagnosed glioblastoma.
First Author: Jiayi Huang